Avenzoar Pharmaceuticals is focused on developing innovative cancer therapeutics, particularly small molecule drugs that target multiple pathways associated with cancer progression and drug resistance. Their lead candidate, AP-001 (also known as Metavert), is a dual inhibitor designed to prevent the growth and metastasis of cancer cells, specifically targeting pancreatic cancer. Pre-clinical studies have shown promising results, indicating that Metavert effectively inhibits pancreatic cancer growth with minimal toxicity. The company plans to initiate clinical trials for Metavert in pancreatic cancer patients in 2025, with potential expansions to lung and liver cancer based on pre-clinical findings.

The company has established a robust pipeline, having secured an exclusive worldwide license agreement with Cedars Sinai Medical Center for the development of three drug candidates: AP-001, AP-002, and AP-003. Avenzoar has also received U.S. patents for their cancer treatment methods and has been awarded a Small Business Technology Grant from the National Cancer Institute. Their strategic approach involves assembling a world-class team of experts and consultants to ensure the successful development of their drug candidates, with a particular emphasis on addressing the challenges posed by metastasis and chemotherapy resistance in cancer treatment.

United States

Avenzoar Pharmaceuticals is a start-up pharmaceutical company founded in 2016. Avenzoar is specialized in developing cancer drugs aiming at targeting and

Avenzoar Pharmaceuticals

Company Details